: : : 2007-10-22 to 2007-10-28
FDA anticipates re-evaluation of the overall risks and benefits of Trasylol
October 26, 2007 06:32
FDA informed healthcare professionals of the Data Safety Monitoring Board's recommendation to stop patient enrollment in the aprotinin treatment group arm of the Blood conservation using antifibrinolytics: A randomized trial in a cardiac surgery population... (Read Article)
